Corvus Pharmaceuticals Initiates Phase 3 Clinical Trial of CPI-006 for Patients with COVID-19

NEXT STORY
Protara Therapeutics to Present at Upcoming Virtual Investor Conferences
PREV STORY
Lateral Flow Assays Market to Reach $13.85 billion by 2027- Exclusive Report Covering Pre and Post COVID-19 Market Analysis and Forecasts by Meticulous Research®
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Verona Pharma Completes Enrollment in Phase 2 Clinical Trial Evaluating Nebulized RPL554 as Add-on to Dual Bronchodilator Therapy for COPD Maintenance Treatment

Enrollment complete ahead of schedule Top line data expected in January 2019 LONDON, Oct. ...

author_avatar
NASDAQ Market News

Novan Reports Second Quarter 2021 Financial Results and Provides Corporate Update

author_avatar
NASDAQ Market News

CytoDyn Reports Preliminary Results from First Five Patients in Phase 2 NASH Open Label Leronlimab Trial. Lower Fatty Deposits in All 5 Patients by as Much as 45% and Lower Fibrosis in 4 Patients by as Much as 10% Compared to Baseline.

author_avatar
NASDAQ Market News